[New Drug Spotlight] Ensifentrine - A New Dual PDE3/4 Inhibitor Approved for COPD Treatment

Ensifentrine (trade name: Ohtuvayre) was approved by the U.S. FDA in June 2024 as a maintenance treatment for adult patients with COPD.